



www.bioinformation.net
Volume 21(8)

Research Article

Received August 1, 2025; Revised August 31, 2025; Accepted August 31, 2025, Published August 31, 2025

DOI: 10.6026/973206300212763

SJIF 2025 (Scientific Journal Impact Factor for 2025) = 8.478

2022 Impact Factor (2023 Clarivate Inc. release) is 1.9

Declaration on Publication Ethics:

The author's state that they adhere with COPE guidelines on publishing ethics as described elsewhere at <https://publicationethics.org/>. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Declaration on official E-mail:

The corresponding author declares that lifetime official e-mail from their institution is not available for all authors

License statement:

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License

Comments from readers:

Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article without open access charges. Comments should be concise, coherent and critical in less than 1000 words.

Disclaimer:

Bioinformation provides a platform for scholarly communication of data and information to create knowledge in the Biological/Biomedical domain after adequate peer/editorial reviews and editing entertaining revisions where required. The views and opinions expressed are those of the author(s) and do not reflect the views or opinions of Bioinformation and (or) its publisher Biomedical Informatics. Biomedical Informatics remains neutral and allows authors to specify their address and affiliation details including territory where required.

Edited by Vini Mehta

E-mail: vmehta@statsense.in

Citation: Batra *et al.* Bioinformation 21(8): 2763-2766 (2025)

Incidence of gestational diabetes mellitus among Indian women

Niti Batra¹, Mohini Ahirwar², Karishma Chaurasia³ & Manik Sirpurkar^{1,*}

¹Department of Obstetrics and Gynecology, Chhindwara Institute of Medical Sciences, Chhindwara, Madhya Pradesh, India;

²Department of Obstetrics and Gynecology, Atal Bihari Vajpayee Government Medical College, Vidisha, Madhya Pradesh, India;

³Department of Obstetrics and Gynecology, Shyam Shah Medical College, Rewa, Madhya Pradesh, India; *Corresponding author

Affiliation URL:

<https://govtmedicalcollegechhindwara.com/>

<https://gmcvidisha.org/>

<https://ssmcrewa.ac.in/>

Author contacts:

Niti Batra - E-mail: drnitibatra29@gmail.com

Mohini Ahirwar - E-mail: mohiniahirwar301@gmail.com

Karishma Chaurasia - E-mail: karishma4015@gmail.com

Manik Sirpurkar - E-mail: drmsirpurkar@gmail.com

Abstract:

Gestational diabetes mellitus (GDM) is a growing public health concern due to its association with adverse maternal and fetal outcomes, yet its risk factors remain under-investigated in many populations. A prospective observational study of 500 pregnant women who presented on regular antenatal visits to CIMS was completed. During 24-28 weeks of gestation, GDM screening was done through a 75-gram Oral Glucose Tolerance Test (OGTT). Regarding socio-demographic, clinical and lifestyle information, standardized questionnaires were used to collect the relevant data and the risk factors were identified by completing a statistical analysis using SPSS version 25 and multivariate logistic regression. We show a substantial incidence of GDM in women attending CIMS antenatal clinics while, age, obesity; family history and reproductive history remain crucial risk determinants.

Keywords: Gestational diabetes mellitus, risk factors, incidence, pregnancy, antenatal care

Background:

Gestational diabetes mellitus (GDM) is either the first recognized carbohydrate intolerance in the context of pregnancy or carbohydrate intolerance of varying severity. The incidences of GDM worldwide range from 1-28 per cent of all pregnancies and drastically vary by the population levels and the methods of screening used [1,2]. The high levels of glucose in maternal bodies expose malnourished mothers and babies to morbidity and mortality, such as macrosomia, hypoglycemia at birth, birth injuries and high chances of contracting type 2 diabetes mellitus in the future [3,4]. India faces an increasing burden of GDM, with prevalence rates ranging from 7.7% to 21.6%, motivated by the rapidity of urbanization, lifestyle change and heightened cases of obesity among women of reproductive age [5]. Determination of risk groups and knowledge of epidemiology in different regions of GDM is still necessary to achieve proper preventative measures and health policy plans [6]. The risk factors that are traditionally related to GDM are advanced maternal age, obesity, a history of diabetes mellitus in the family, previous GDM, polycystic ovarian syndrome (PCOS), multiparity and prior macrosomic infants [7]. However, variations across geographical regions, ethnicity and socioeconomic status suggest the need for localized studies to inform region-specific interventions [8]. Therefore, it is of interest to bridge this gap by evaluating the incidence of GDM and investigating associated socio-demographic and clinical risk factors among women attending antenatal clinics at CIMS, a tertiary care teaching hospital serving a diverse local population.

Materials and Methods:**Study design and setting:**

The setting where a prospective observational study took place is at Antenatal Clinic of Chhindwara Institute of Medical Sciences (CIMS), Chhindwara, MP, India and was performed between August 2024 and July 2025, after approval from the Institutional Ethics Committee [Ref. No. CIMS/EC/2024/8513].

Participants:

Three hundred and fifty pregnant women between the ages of 18-40 who were attending the antenatal clinics were enrolled

after giving informed consent. Pre-existing diabetes mellitus, chronic systemic illness, or unwillingness to participate proved to be known exclusion criteria.

Data collection:

The screen was carried out on all subjects at 24-28 weeks of gestation with a 75-gram Oral Glucose Tolerance Test (OGTT) according to IADPSG criteria. GDM was defined as fasting glucose level of ≥ 92 mg/dl, 1 hour ≥ 180 mg/dl and/or 2 hours ≥ 153 mg/dL. Structured questionnaires (socio-demographic and clinical-related data, such as age, BMI, parity, family history and past obstetric history) were used to collect data.

Statistical analysis:

The analysis of data was done in SPSS version 25. A descriptive statistic, Chi-square and logistic regression were carried out. A p-value < 0.05 was taken to be significant.




Figure 1: Incidence of GDM by BMI classification

Results:

The study enrolled 500 pregnant women, of whom 62 (12.4%) received a Gestational Diabetes Mellitus (GDM) diagnosis. It was found that there were considerable links between certain

risk factors and the occurrence of GDM. Women ≥ 30 years had significantly higher incidence (OR=3.02; 95% CI: 1.61–5.67; $p=0.002$) (**Table 1**). Elevated BMI (>25 kg/m²) doubled the risk (OR=2.87; 95% CI: 1.54–5.33; $p<0.001$) (**Table 2, Figure 1**). Multiparity and family history significantly increased GDM risk, while prior macrosomic birth or stillbirth also correlated significantly ($p<0.05$) (**Table 3**). History of abortion, hypothyroidism and Multigravida showed a statistically significant association with GDM ($p < 0.05$). Sedentary lifestyle, present in 36 of the GDM-positive women, emerged as one of the

most significant modifiable risk factors ($p = 0.003$). In contrast, higher parity (≥ 2) did not show a significant association with GDM ($p = 0.312$), suggesting that parity alone may not be a reliable predictor in this population. These findings highlight the multifactorial nature of GDM and underscore the importance of early identification and lifestyle interventions in high-risk groups (**Table 4**). **Figure 2** shows the comparison of risk factor distribution between GDM and non-GDM groups.

Table 1: Incidence of GDM by maternal age

Maternal Age Group	GDM Positive (n=62)	GDM Negative (n=438)	Percentage (%)	P-value
≤30 years	20	298	6.3%	0.002*
>30 years	42	140	23.1%	

*Significant

Table 2: Incidence of GDM by body mass index (BMI)

BMI (kg/m ²)	GDM Positive (n=62)	GDM Negative (n=438)	Percentage (%)	P-value
<30	15	292	4.9%	<0.001*
≥30	47	146	24.3%	

*Significant

Table 3: Incidence of GDM based on family history of diabetes

Family History of Diabetes	GDM Positive (n=62)	GDM Negative (n=438)	Percentage (%)	P-value
Yes	30	104	22.4%	<0.001*
No	32	334	8.7%	

*Significant

Table 4: Incidence of GDM

Risk Factors	GDM Positive (n=62)	GDM Negative (n=438)	Percentage (%)	P-value
PCOS	18	60	23.1%	0.001*
Multigravida	40	281	64.0%	0.045*
Parity ≥2	26	174	40.0%	0.312
History of abortion	12	48	12.0%	0.037*
Previous macrosomic baby	16	61	20.8%	0.004*
Sedentary lifestyle	36	120	31.2%	0.003*
Hypothyroidism	10	35	9.0%	0.042*

*Significant




Figure 2: Comparison of risk factor distribution between GDM and non-GDM groups

Discussion:

This study highlights a GDM incidence rate of 14.9%, consistent with previous reports from India that range from 7.7% to 21.6% [5]. The findings underscore the necessity of structured universal screening strategies in antenatal settings to enhance early

detection and management, ultimately reducing maternal-fetal morbidity and mortality. Advanced maternal age emerged as a substantial risk factor for GDM, aligning with global epidemiological patterns [2,3]. Increased maternal age potentially exacerbates insulin resistance and beta-cell dysfunction due to chronic low-grade inflammation and progressive decline in insulin sensitivity [1, 4]. Obesity's prominent role in GDM development was confirmed, with overweight or obese women exhibiting significantly elevated risk due to adiposity-driven insulin resistance [6,8]. Family history of diabetes mellitus is recognized as a genetic and environmental risk factor, indicative of a pre-existing predisposition toward insulin resistance or beta-cell dysfunction, further increasing pregnancy-related metabolic stress [4]. Multiparity and adverse obstetric histories [9-11], including macrosomia and stillbirth, emphasize the cumulative effect of insulin resistance and inadequate glycemic control across pregnancies [7,8,12]. Local epidemiological data from this study necessitate tailored interventions at antenatal clinics emphasizing lifestyle modification, dietary counseling and regular monitoring for high-risk groups. Future research should further explore interventions and cost-effective screening

strategies tailored to regional needs, addressing socio-cultural and demographic variations in Chhindwara, Madhya Pradesh [13-17].

Conclusion:

A significant incidence of GDM among women attending antenatal clinics at CIMS, Chhindwara, underscoring the importance of routine screening in high-risk groups is shown. Maternal age, elevated BMI, family history of diabetes mellitus and multiparity significantly increase GDM risk. Clinicians should focus on preventive strategies, individualized management plans and increased awareness to minimize adverse maternal-fetal outcomes.

References:

- [1] Dam N *et al.* *Diabetes Asia Journal*. 2025 **2**:21. [DOI: 10.62996/daj.54042025]
- [2] Mantri N *et al.* *BMC Public Health*. 2024 **24**:527. [DOI: 10.1186/s12889-024-18024-9]
- [3] Gracelyn LJ & NS. *Int J Reprod Contracept Obstet Gynecol*. 2016 **5**:285. [DOI: 10.18203/2320-1770.ijrcog20160081]
- [4] Gupta K *et al.* *Int J Med Res Rev*. 2025 **3**:162. [DOI: 10.17511/IJMRR.2015.12.029]
- [5] Bahl S *et al.* *BMC Pregnancy and Childbirth*. 2022 **22**:32. [PMID: 35031013]
- [6] Gupte S *et al.* *Int J Diabetes Dev Ctries* 2023 **43**:511. [DOI: 10.1007/s13410-023-01198-0]
- [7] Mustaniemi S *et al.* *Endocr Connect*. 2018 **7**:859. [PMID: 29858213]
- [8] Ye W *et al.* *BMJ*. 2022 **377**:e067946. [PMID: 35613728]
- [9] Alduayji MM & Selim M. *Cureus*. 2023 **15**:e44200. [PMID: 37767263]
- [10] Dissassa HD *et al.* *BMJ Open*. 2023 **26**:e073339. [PMID: 37751960]
- [11] Mdoe MB *et al.* *BMJ Nutr Prev Health*. 2021 **4**:69. [PMID: 34308114]
- [12] Larebo YM *et al.* *Biomed Res Int*. 2021 **2021**:5564668. [PMID:33880369]
- [13] Lagakodie S *et al.* *Malays Fam Physician*. 2017 **12**:9. [PMID:29423124]
- [14] Muche AA *et al.* *BMC Pregnancy Childbirth*. 2019 **19**:334. [PMID: 31519151]
- [15] Yahaya TO *et al.* *Egyptian J MedHuman Genetics*. 2020 **21**:13. [DOI:10.1186/s43042-020-00054-8]
- [16] Nigatu B *et al.* *Clin Diabetes Endocrinol*. 2022 **8**:2. [PMID: 35197130]
- [17] Meharry MP *et al.* *Diabetes Res Clin Pract*. 2019 **151**:252. [PMID: 30946850]